found to have a lower risk of developing Alzheimer’s disease when treated with GLP-1s.
The potential for GLP-1 drugs to treat addiction is another exciting development. Dr. Mo Sarhan’s success in using Mounjaro to help his patients overcome cravings for opioids and alcohol is just the beginning. With Eli Lilly planning to conduct large studies on the use of GLP-1s in addiction treatment, there is hope for a new approach to addressing substance abuse.
Overall, the expanding use of GLP-1 drugs beyond their original focus on obesity and diabetes is a promising development in the field of medicine. As more research is conducted and more patients benefit from these drugs, the potential for improving a wide range of health conditions continues to grow.